Vascular complications have emerged as the major cause of mortality and morbidity when using the large catheters required for percutaneous aortic valve replacement (PAVR) (1) (2) (3) (4) . Studies have yielded a wide range of vascular complication rates, influenced by clinical factors, but also by nonuniform definitions of what constitutes a vascular complication and by diagnostic rigor (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . For instance, the large 22-to 24-F sheaths required for the SAPIEN valve (Edwards Lifesciences Inc., Irvine, California) were associated with vascular complication rates of 22.9% in the large European SOURCE (SAPIEN Aortic Bioprosthesis European Outcome) registry (4) and 30.7% in the rigorously monitored North American PARTNER 1B (Placement of Aortic Transcatheter Valves) trial (1) . The smaller 18-F sheaths required for the third-generation CoreValve delivery system (Medtronic Inc., Minneapolis, Minnesota) have been associated with lower reported vascular complication rates, ranging from 1.9% to 13.3% (3, 5, 6, 10, 11) . Vascular complication rates with the similarly low-profile 18-to 19-F SAPIEN XT NovaFlex delivery system (Edwards Lifesciences Inc. ) are not yet available.
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Recently, the Valve Academic Research Consortium (VARC) proposed standardized definitions for clinical endpoints in transcatheter valve procedures in an effort to allow comparison between clinical trials (Table 1) (12, 13) . The aim of this study was to evaluate vascular complications in a consecutive patient population undergoing PAVR using current techniques applying current VARC definitions.
Methods
Study population. All patients undergoing transfemoral PAVR at our center between April 2009 and March 2011 were enrolled into a prospective registry. Femoral arterial access was the default transcatheter approach, with apical or axillary access used in the presence of small or diseased iliofemoral arteries. All patients gave written informed consent. Patients were assessed at baseline, after the procedure, at hospital discharge, and at 30 days. Inc., Bloomington, Indiana) was used to facilitate estimation of minimal arterial diameter. We used peripheral angiography at the time of routine cardiac catheterization as the initial evaluation of vascular access, and, if access appeared borderline, multidetector computed tomographic angiography (MDCT) was used to further evaluate arterial diameter and the distribution and extent of calcification.
A subset of patients (n ϭ 82) were also screened with MDCT performed on a 64-slice Discovery HD 750 High Definition scanner (GE Healthcare, Milwaukee, Wisconsin). Minimal luminal diameter measurements were performed by measuring perpendicular to the vessel axis. Tortuosity was determined on the basis of the most severe angulation of the right iliofemoral system in anterior/ posterior or medial/lateral direction.
Fluoroscopic calcification was graded as none, mild (some calcification), moderate (the course of the artery can be seen without injection of contrast dye), or severe (heavily calcified iliofemoral arteries). MDCT calcification was graded similarly. Arterial access. The screening angiogram and MDCT were reviewed, and the side with the larger, less tortuous, less diseased iliofemoral artery was selected for insertion of the large sheath. The proposed puncture site was routinely assessed with fluoroscopy to assure its position relative to the femoral head and prior angiogram. When necessary, a catheter was advanced from the contralateral femoral artery, or ultrasound was utilized to guide puncture. In a subset of patients, 14-to 18-F expandable sheaths where used and expanded to 18-to 19-F after insertion. Anticoagulation. Patients were pre-medicated with aspirin 325 mg and clopidogrel 300 mg before the procedure. After introduction of the large sheath, heparin was administered to achieve an activated clotting time of Ͼ250 s. Protamine reversal was used only in patients with ongoing bleeding. Arterial closure. In all but 1 patient, pre-closure was performed using either 2 ProGlide devices (sutures implanted at 10 and 2 o'clock) or 1 Prostar device (Abbott Vascular Inc, Redwood City, California). After closure, contralateral iliofemoral angiography was performed unless the total amount of contrast dye was felt to be too high in relation to the patient's Preclosure successfully achieved hemostasis. However, routine cross-over femoral angiography showed occlusion of the common femoral artery with a likely thrombus (A). This was dilated with a balloon using a cross-over technique (B, arrow) with residual mild stenosis (C, arrow). Recovery was uneventful.
Baseline Characteristics in Patients Without and With Vascular Complications (n ‫؍‬ 137) 
Results
A total of 137 patients were analyzed, with the Edwards SAPIEN XT valve implanted in 96 patients, SAPIEN in 25 patients, Medtronic CoreValve in 11 patients, and miscellaneous prototype valves (all using an 18-F sheath) in 5 patients. Arterial closure. Pre-closure with either 2 ProGlide (n ϭ 131) or 1 ProStar (n ϭ 5) was used routinely. One patient underwent planned surgical cut-down at the surgeon's request. Cross-over angiography to assess the femoral access site after percutaneous closure was performed in 89 patients (65%), documenting a mean residual stenosis of 38 Ϯ 18% with femoral occlusion in 3 patients, 1 of whom underwent surgical and 2 percutaneous treatment (Fig. 2) . Vascular complications. Minor and major vascular complications occurred in 24 patients (18%); all but 2 were iliofemoral. Major complications occurred in 5 patients (4%), dissection or perforation of the iliac artery in 4 (3%), and guidewire perforation of the left ventricle in 1 (1%). Minor vascular complications occurred in 19 patients (14%), with femoral bleeding, stenosis, or occlusion in 16 patients (12%), pseudoaneurysm in 2 (1%), and retroperitoneal bleeding in 1 (1%). Unplanned vascular surgery was performed in 16 patients (12%). No aortic rupture or dissection was observed, despite documented porcelain aorta in 7 (5%). Table 2 summarizes baseline characteristics of patients without and with vascular complications. Vascular complications were more common in patients with peripheral vascular disease and when the minimal artery diameter exceeded the external sheath diameter (Fig. 3 ). There were no intraprocedural deaths. Mortality at 30 days was 5.1%; deaths were due to heart failure (n ϭ 2), sudden death (n ϭ 2), pneumonia (n ϭ 2), and ischemic bowel (n ϭ 1). No patient with a minor vascular complication died, whereas 1 of 5 patients with a major complication died within 30 days. Hospital stay was longer in patients with major vascular complications than in those with minor or no complications (16 Ϯ 17 days, 11 Ϯ 8 days, and 6 Ϯ 4 days, respectively, p Ͻ 0.01). Changes over time. As shown in Table 3 and Figure 4 , procedural characteristics and outcome differed between 2009 and 2010. In 2010, the smaller 18-to 19-F sheaths were used in all but 2 patients. MDCT for additional screening of the iliofemoral arteries, ultrasound-guided puncture, and expandable sheaths were used more frequently.
Vascular complications fell from 32% in 2009 to 9% in 2010 (p Ͻ 0.01). Major complications fell from 8% to 1% (p ϭ 0.05), minor complications fell from 24% to 8% (p Ͻ
The rate of vascular complications (major and minor combined) was higher when minimal artery diameter was smaller than the external sheath diameter (24% vs. 10%, p ϭ 0.03). Such patients also required more unplanned surgery. art. ϭ artery; min. ϭ minimal. Values are n (%) or mean Ϯ SD. *Expandable sheaths measured 14-to 18-F and are expanded after insertion to accommodate larger valves.
Changes in Procedural Characteristics and Outcome Over Time
MDCT ϭ multidetector computed tomographic angiography.
0.01), major bleeds fell from 14% to 1% (p Ͻ 0.01), and unplanned surgery fell from 28% to 2% (p Ͻ 0.01). Iliofemoral arterial screening using MDCT. MDCTdetermined minimal artery diameter less than sheath external diameter was a strong predictor for vascular complications (23% vs. 5%, p ϭ 0.01), as was the presence of moderate or severely calcified iliofemoral arteries (29% vs. 9%, p ϭ 0.03) ( Table 4 ). Complications associated with moderate or severely calcified iliofemoral arteries included femoral access site stenosis requiring balloon dilation, access site bleeding requiring a covered stent in 1 patient and surgical repair in 1 patient, and iliofemoral artery dissection/ perforation requiring treatment in 2 patients.
Discussion
Vascular complications decreased dramatically over the study period. From 2009 to 2010, major vascular complications fell from 8% to 1%, minor vascular complications fell from 24% to 8%, and unplanned vascular surgery fell from 28% to 2%. As might be expected, the reduction in vascular complications was associated with a reduction in major bleeding from 14% to 1%, the need for blood transfusion from 22% to 7%, and hospital length of stay from 7.7 to 6.8 days.
Percutaneous access closure was used in some cases in 2008 and in all but 1 case in 2009 and 2010. This period saw a gradual transition from 22-to 24-F sheaths to smaller 18-to 19-F sheaths and then even smaller expandable sheaths. Vascular screening and patient selection with angiography and MDCT became more rigorous and routine. Experience with percutaneous vascular closure techniques increased, and these were increasingly reliable. When vascular injury did occur or when hemostasis was unsuccessful, percutaneous repair techniques (balloon occlusion or dilation, stenting) were more frequently used, increasing from 13% to 63% over the study period. It was apparent that most complications could be managed percutaneously.
Comparison with previous studies. The most common complications associated with PAVR are vascular, and most bleeding complications are the result of vascular injury. Vascular and bleeding complications have been shown to be a major cause of morbidity and mortality (1) . Reported vascular complications rates vary widely from 1.9% to 30.7% (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Unfortunately, nonuniform definitions and variable diagnostic rigor prevent direct comparisons between studies. However, the combined effect of increased experience and smaller sheath size has been previously demonstrated (14, 15) . Our study further documents sheath diameter and iliofemoral calcification as predictors of complications. The risk for vascular complications is higher in patients with a minimal iliofemoral artery diameter that is smaller than the external sheath diameter (as determined by angiography or MDCT), in the presence of moderate or severe calcification (as determined by MDCT), and in patients with peripheral vascular disease. Even so, most such patients underwent PAVR without vascular complications, suggesting the importance of balancing the potential for risk and benefit.
Conclusions
Vascular complications occur more often if the minimal artery diameter is smaller than the sheath external diameter, in the presence of moderate or severe calcification, and in patients with peripheral vascular disease. Open surgical access and closure of the femoral artery has been advocated to reduce complication rates when using the large sheaths required for PAVR. However, this study suggests that with careful patient selection and advanced interventional techniques, very low complication rates can be achieved with a fully percutaneous procedure. Values are mean Ϯ SD or n (%).
